TRANSFECTION REAGENTS AND EQUIPMENT MARKET ANALYSIS

The global transfection reagents and equipment market was valued at US$ 1,066.5 Mn in 2022 and is forecast to reach a value of US$ 2,171.7 Mn by 2030 at a CAGR of 9.3% between 2023 and 2030. The global transfection reagents and equipment market is experiencing strong growth owing to the rise in burden of chronic diseases worldwide and rise in demand for transfection reagents and equipment. Moreover, increase in focus on the development of novel therapies and increase in research and development (R&D) across the globe is expected to boost the growth of the market. However, factors such as high cost of transfection reagents and selective effectiveness and certain limitations of transfection reagents are expected to hamper the market growth.

Global Transfection Reagents and Equipment Market: Regional Insights

Based on geography, the global transfection reagents and equipment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Among regions, North America is expected to gain highest share in the market over the forecast period owing to the rising application of transfection procedures, increase in demand for synthetic genes, and development of novel techniques for transient and stable transfection in the region. For instance, synthetic genes are widely applied in therapy and treat various diseases such as cancer, cardiovascular diseases, metabolic disease, neurodegenerative diseases, etc. According to the U.S. Centers for Disease Control and Prevention (CDC), chronic diseases such as heart disease, cancer, and diabetes are the leading causes of death and disability in the United States.

Asia Pacific is also expected to witness robust growth in the global transfection reagents and equipment market owing to the rising application of transfection procedures, developments in the field of recombinant technology and proteomics, and rising support from government and public bodies in the region. For instance, in the Union Budget 2021-22, the government of India allocated 1,660 crore for biotechnology research and development in the country. The Indian Government also announced its plan to set up nine biosafety level-3 (BSL-3) laboratories through the Pradhan Mantri Aatmanirbhar Swasth Bharat Yojana Scheme.

Figure 1. Global Transfection Reagents and Equipment Market Share (%), by Region, 2023

To learn more about this report, request sample copy

Global Transfection Reagents and Equipment Market Drivers:

Rise in burden of chronic diseases to propel market growth

One of the key factors expected to propel growth of the global transfection reagents and equipment market during the forecast period is the rise in burden of chronic diseases worldwide. For instance, such a high burden of chronic diseases leads to an increase in demand for synthetic genes, driving the market growth. Synthetic genes are widely applied in therapy and treat various diseases such as cardiovascular diseases and cancer. As per the World Health Organization (WHO), cancer and cardiovascular diseases (CVDs) are the leading cause of death across the globe, taking an estimated 10 million and 17.9 million lives each year, respectively.

High demand for to transfection reagents and equipment drive market growth

Another factor which is driving growth of the global transfection reagents and equipment market is the increase in demand for transfection reagents and equipment across the globe. For instance, in August 2021, Polypus Transfection SA launched FectoVIR-AAV GMP transfection reagent for large-scale viral vector production to overcome gene and cell therapy manufacturing barriers. The company has also been scaling up of late in order to ensure it can supply transfection reagents to the CGT sector for the next two decades. This in turn is expected to augment growth of the global transfection reagents and equipment market.

Global Transfection Reagents and Equipment Market Opportunities:

Rise in focus on the development of potential in vivo therapies is expected to provide significant growth opportunities for players in the transfection reagents and equipment market. For instance, players in the market are focusing on developing and launching novel potential in vivo therapies in the market to meet growing demand. In July 2020, Polyplus-transfection announced the launch of its GMP-compliant residual test for its PEIpro product portfolio, transfection reagents designed for process development, pre-clinical, clinical, and commercial lentivirus, and Adeno-Associated Virus (AAV) production for cell and gene therapies.

Increase in research and development (R&D) across the globe is expected to offer lucrative growth opportunities for players in the global transfection reagents and equipment market. For instance, in November 2020, Eli Lilly and Company and Precision BioSciences, Inc. announced a research collaboration and exclusive license agreement to use Precision BioScience’ proprietary ARCUS genome editing platform for the research and development of potential in vivo therapies for genetic disorders, with an initial focus on Duchenne Muscular Dystrophy and two other undisclosed gene targets. This in turn is also expected to boost growth of the market.

Global Transfection Reagents and Equipment Market Trends:

Need for early diagnosis is a recent trend

Over the years, the use of biopharmaceutical products has increased significantly for the treatment of many pathological conditions, such as cancer and genetic diseases, among others. With the rise in burden of such diseases, the need for early diagnosis and treatments is also increasing rapidly. Thus, players in the market have increased their investment and research for the development of such therapies (transfection reagent and equipment are highly required in such research processes). This trend is expected to continue during the forecast period.

Need for novel therapies/treatment is another trend

Pharmaceutical and biotechnology companies are on a continuous hunt for identifying new therapy and treatment for the diseases, as the burden of life-threatening diseases increases, synthetic genes and genomics have become an attractive area for investment, and is expected to offer tremendous opportunities for players in the market. Moreover, players in the market collaborating or signing partnership agreements to enhance their production and commercialization capabilities. This trend is also expected to continue over the forecast period.

Global Transfection Reagents and Equipment Market Restraints:

High cost of transfection reagents to hinder market growth

One of the key factors expected to hinder growth of the global transfection reagents and equipment market is the high cost of transfection reagents. Transfection involves research at the genetic and molecular level, which needs precise and sophisticated reagents. For large-scale applications, the amount of reagent required is considerably high, which in turn increase the cost of the reagent. For instance, the Lipofectamine 3000 transfection reagent (0.75 ml) by ThermoFisher Scientific costs INR 38,559 and the ViaFect Transfection Reagent (0.75 ml) by Promega costs INR 27,975. This in turn is expected to hinder growth of the market.

Limitations of transfection reagents to hamper market growth

Another factor which is hampering the growth of the global transfection reagents and equipment market is the selective effectiveness and certain limitations of transfection reagents. For instance, as the transfection involves the insertion of nucleic acids into the eukaryotic cells, the effectiveness of the certain limitations may hamper the process in reagents or effectiveness of the process. The process's effectiveness depends highly on the selection of reagents. The selective effectiveness and limitations of reagents significantly affect the results of the process and may restrain growth of the market during the forecast period.

Figure 2. Global Transfection Reagents and Equipment Market Share (%), by Product, 2023

To learn more about this report, request sample copy

Global Transfection Reagents and Equipment Market Segmentation:

The global transfection reagents and equipment market report is segmented into Product, Method, End User, and Geography.

Based on Product, the market is segmented into Reagents and Equipment. Of which, Reagents Segment is expected to dominate the transfection reagents and equipment market over the forecast period and this is attributed to the increasing demand for transfection reagents.

Equipment Segment is also expected to witness significant growth in the near future and this is due to the development of novel techniques for transient and stable transfection. These equipment are widely used in the transfection process.

Based on Method, the market is segmented into Biochemical Methods, Physical Methods, and Viral Methods. Out of which, Biochemical Methods Segment is expected to dominate the market over the forecast period and this is attributed to the rise in biochemical transfection. Biochemical transfection involves the use of chemical reagents. Since the biochemical methods are easy to use and less expensive, the use of biochemical method is increasing worldwide.

Physical Methods Segment is also expected to witness significant growth in the near future and this is owing to rise in implementation of physical transfection. This method is often employed to transfect difficult-to-transfect cells such as primary cells, stem cells, and B cell lines.

Based on End User, the market is segmented into Pharmaceutical and Biotechnology Companies and Academics and Research Institutes. Out of which, Pharmaceutical and Biotechnology Companies Segment is expected to dominate the market over the forecast period and this is attributed to the growing burden of diseases and increase in demand or use of transfection reagent and equipment across the globe.

Global Transfection Reagents and Equipment Market: Key Developments

In August 2021, Mirus Bio announced the launch of the TransIT VirusGEN GMP product line. This expansion to the existing TransIT VirusGEN product line complies with good manufacturing practice (GMP) viral vector manufacturing to support cell and gene therapy development and process activities through to GMP commercial scale.

In June 2021, Qiagen NV launched QIAprep&amp CRISPR Kit and CRISPR Q-Primer Solutions that allow researchers to analyze edited genetic material with unparalleled speed and efficiency to determine how their interventions have changed the function of the DNA sequence.

In May 2021, Lonza Group announced the launch of the Next Generation 4D-Nucleofector Cell Transfection Platform with proven performance and enhanced ease of use.

In April 2021, BOC Sciences launched the new generation non-viral in vivo transfection reagents platform to deliver a variety of samples to targeted organs (including kidney, liver, and pancreas).

Global Transfection Reagents and Equipment Market: Key Companies Insights

The global transfection reagents and equipment market is highly competitive. This is attributed to the rise demand for long-term pain management from geriatric population, as a result, players in the market are focusing on launching novel products in the market.

Some of the key players in the global transfection reagents and equipment market are Qiagen NV, Promega Corporation, Polyplus-transfection SA, Mirus Bio LLC, Merck KgaA, MaxCyte Inc., Lonza Group, Bio-Rad Laboratories Inc., and Thermo Fisher Scientific Inc., among others.

*Definition: Transfection is a process of introducing nucleic acids into eukaryotic cells by non-viral methods. The reagents and equipment used in this procedure are referred to as transfection reagents and equipment.